company background image
LRMR logo

Larimar Therapeutics NasdaqGM:LRMR Stock Report

Last Price

US$7.08

Market Cap

US$451.7m

7D

-2.6%

1Y

88.3%

Updated

27 May, 2024

Data

Company Financials +

Larimar Therapeutics, Inc.

NasdaqGM:LRMR Stock Report

Market Cap: US$451.7m

LRMR Stock Overview

A clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.

LRMR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Larimar Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Larimar Therapeutics
Historical stock prices
Current Share PriceUS$7.08
52 Week HighUS$13.68
52 Week LowUS$2.18
Beta0.77
1 Month Change9.94%
3 Month Change-39.69%
1 Year Change88.30%
3 Year Change-14.80%
5 Year Changen/a
Change since IPO-42.44%

Recent News & Updates

Recent updates

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Nov 13
We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

May 19
Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 02
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Laramar Therapeutics issued patent for lead pipeline candidate

Oct 20

Larimar Therapeutics prices ~$70M stock offering

Sep 14

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Sep 02
Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Larimar Therapeutics GAAP EPS of -$0.47

Aug 11

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Mar 21
We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Dec 18
Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Larimar under pressure as FDA puts clinical hold on CTI-1601 program

May 26

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 08
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Larimar, Avadel, Applied Therapeutics will added to Nasdaq Biotechnology Index

Dec 15

Larimar completes dosing in Friedreich’s Ataxia, provides program update

Dec 08

Larimar Therapeutics (LRMR) Investor Presentation - Slideshow

Nov 16

Larimar Therapeutics reports Q3 results

Nov 10

Shareholder Returns

LRMRUS BiotechsUS Market
7D-2.6%-1.6%-0.2%
1Y88.3%7.4%25.6%

Return vs Industry: LRMR exceeded the US Biotechs industry which returned 7.4% over the past year.

Return vs Market: LRMR exceeded the US Market which returned 25.6% over the past year.

Price Volatility

Is LRMR's price volatile compared to industry and market?
LRMR volatility
LRMR Average Weekly Movement10.0%
Biotechs Industry Average Movement11.2%
Market Average Movement5.9%
10% most volatile stocks in US Market16.0%
10% least volatile stocks in US Market2.8%

Stable Share Price: LRMR's share price has been volatile over the past 3 months.

Volatility Over Time: LRMR's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a42Carole Ben-Maimonwww.larimartx.com

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Larimar Therapeutics, Inc. Fundamentals Summary

How do Larimar Therapeutics's earnings and revenue compare to its market cap?
LRMR fundamental statistics
Market capUS$451.72m
Earnings (TTM)-US$45.08m
Revenue (TTM)n/a

0.0x

P/S Ratio

-10.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LRMR income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$45.08m
Earnings-US$45.08m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.71
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did LRMR perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.